Compare RGCO & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | AARD |
|---|---|---|
| Founded | 1912 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.9M | 231.9M |
| IPO Year | N/A | 2025 |
| Metric | RGCO | AARD |
|---|---|---|
| Price | $22.50 | $14.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.63 |
| AVG Volume (30 Days) | 8.8K | ★ 194.4K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $95,334,212.00 | N/A |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $8.30 | N/A |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.06 | $4.88 |
| 52 Week High | $23.82 | $19.58 |
| Indicator | RGCO | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 68.03 |
| Support Level | $21.86 | $12.54 |
| Resistance Level | $22.42 | $14.29 |
| Average True Range (ATR) | 0.59 | 0.95 |
| MACD | 0.01 | 0.57 |
| Stochastic Oscillator | 75.37 | 86.43 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.